The Moderating Role of Genetics on the Effectiveness of the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) Program on Cognitive Impairment.

This article focuses on a clinical trial investigating how genetic variants moderate the effects of the Mindfulness-Based Stress Reduction program adapted for breast cancer survivors (MBSR(BC)) on cognitive functioning and symptoms. Among 128 non-Hispanic White breast cancer survivors who completed chemotherapy or chemotherapy plus radiation, three single nucleotide polymorphisms (SNPs)—rs4680 in COMT, rs1800497 in ANKK1, and rs6277 in DRD2—were identified as significant moderators influencing cognitive improvements following MBSR(BC). Although effect sizes were generally small, these findings suggest that genetic profiles may help predict which survivors benefit most from mindfulness interventions, supporting the potential development of personalized, genotype-tailored survivorship care. Limitations include a relatively small sample size for genetic analysis and restriction to non-Hispanic White participants, which may affect generalizability.